Want to see LFWD full AI Analyst Report?
LFWD Stock Chart & Stats
$7.11
-$0.16(-2.30%)
At close: 4:00 PM EDT
$7.11
-$0.16(-2.30%)
Day’s Range― - ―
52-Week Range$4.14 - $10.56
Previous CloseN/A
Volume3.69K
Average Volume (3M)316.99K
Market Cap
$19.98M
Enterprise Value$8.06
Total Cash (Recent Filing)$11.42M
Total Debt (Recent Filing)$8.81M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 12, 2026EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.66
Shares Outstanding2,814,409
10 Day Avg. Volume318,606
30 Day Avg. Volume316,993
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside40.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.43
Revenue Forecast (FY)$28.29M
Bulls Say, Bears Say
Bulls Say
Improved Liquidity From Financing & AcquisitionThe $10M convertible financing plus ~$6.5M of cash from the Oratech acquisition lifted unrestricted cash to $11.4M from $2.2M, materially extending runway. This stronger liquidity reduces near-term refinancing pressure and gives management time to stabilize operations and execute backlog shipments into 2026–2027.
Product Traction And Reimbursement ExpansionReWalk personal exoskeletons growing 11% YoY, aided by international distribution and expanding payer coverage, shows durable product-market fit. Expanded Medicare Advantage coverage and distribution networks enlarge the addressable market and improve conversion prospects for clinics and personal users over the medium term.
Lower Cash Burn And Reduced Adjusted OpexA 12% decline in adjusted operating expenses and a 33% reduction in operating cash burn reflect improved cost discipline and working-capital management. These operational gains make the business more resilient, lowering the frequency and size of future financing needs if revenue trends stabilize.
Bears Say
Zero Reported Shareholders' EquityReporting zero stockholders' equity despite modest debt indicates minimal balance-sheet cushion. Combined with ongoing losses, this weak equity position elevates insolvency and dilution risk over months if the company cannot sustain positive cash flow or secure further financing on reasonable terms.
Revenue Decline And Execution RiskA 22% quarterly revenue decline driven by supply, facility transition and AlterG shipment timing highlights execution vulnerability. Management expects catch-up into Q2–Q3, but manufacturing transitions and backlog fulfillment risk could delay recovery and extend top-line pressure over the medium term.
Material Gross Margin CompressionAn ~800bp gross margin hit driven largely by unfavorable FX and tariffs plus lower manufacturing absorption signals structural cost headwinds. Unless addressed via pricing, sourcing changes or scale, these pressures can persist and materially constrain the path to sustainable profitability.
Lifeward News
LFWD FAQ
What was Lifeward’s price range in the past 12 months?
Lifeward lowest stock price was $4.14 and its highest was $10.56 in the past 12 months.
What is Lifeward’s market cap?
Lifeward’s market cap is $19.98M.
When is Lifeward’s upcoming earnings report date?
Lifeward’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.
How were Lifeward’s earnings last quarter?
Lifeward released its earnings results on May 15, 2026. The company reported -$3.13 earnings per share for the quarter, missing the consensus estimate of -$1.18 by -$1.95.
Is Lifeward overvalued?
According to Wall Street analysts Lifeward’s price is currently Undervalued.
Does Lifeward pay dividends?
Lifeward does not currently pay dividends.
What is Lifeward’s EPS estimate?
Lifeward’s EPS estimate is -1.39.
How many shares outstanding does Lifeward have?
Lifeward has 2,814,409 shares outstanding.
What happened to Lifeward’s price movement after its last earnings report?
Lifeward reported an EPS of -$3.13 in its last earnings report, missing expectations of -$1.18. Following the earnings report the stock price went up 1.592%.
Which hedge fund is a major shareholder of Lifeward?
Currently, no hedge funds are holding shares in LFWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lifeward
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
LFWD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.View all LFWD earnings summariesLFWD Stock 12 Month Forecast
Average Price Target
$10.00
▲(40.65% Upside)
Technical Analysis
Ownership Overview
29.44% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
70.55% Public Companies and
Individual Investors